Feldstein’s participation reflects the growing interest of major pharmaceutical companies in aging-related biology as a source of therapeutic opportunities. Rather than treating aging as a single disease, geroscience investigates the interconnected biological processes that increase vulnerability to multiple age-associated conditions. These processes can include cellular senescence, chronic inflammation, mitochondrial dysfunction, loss of proteostasis, epigenetic alterations, impaired tissue repair and declining immune function. Researchers increasingly hope that interventions aimed at these mechanisms could delay or reduce the risk of several diseases simultaneously, extending the period of life spent in good health rather than merely increasing total lifespan.

That scientific shift has created a new class of drug-development questions. Researchers must determine which biological features of aging are causally responsible for disease, which can be safely modified, and how those changes can be measured in humans. Potential indicators include molecular signatures in blood, DNA-methylation patterns, inflammatory markers, imaging measurements, physical-performance data and composite assessments of biological age. Yet a biomarker is not automatically a therapeutic target, and a change in biological age does not necessarily demonstrate that a treatment will prevent disease. Establishing clinically meaningful endpoints remains one of the central challenges facing longevity medicine.

“The biology of aging has become one of the most promising frontiers in biomedical science,” said Vadim Gladyshev, executive chair of ARDD and professor of medicine at Harvard University. He said the field must combine a deeper understanding of aging with the development of interventions that improve healthspan, the period of life spent in relatively good health. According to Gladyshev, progress will require collaboration across disciplines and sectors, because discoveries in molecular biology must ultimately be tested through rigorous translational and clinical research.

ARDD 2026 is being presented as a meeting point between those stages of discovery. Academic laboratories are investigating the molecular architecture of aging, while biotechnology companies are developing programs designed to influence senescent cells, immune aging, metabolic regulation, tissue regeneration and other age-related pathways. Pharmaceutical companies bring experience in medicinal chemistry, toxicology, clinical-trial design, manufacturing and regulatory strategy. Investors, meanwhile, are evaluating whether emerging longevity technologies can produce reproducible clinical benefits at a scale compatible with modern health-care systems.

The conference will include leaders from ten of the world’s major pharmaceutical companies and a broad network of sponsors from the pharmaceutical, biotechnology, nutrition, diagnostics, finance and consumer-health sectors. Insilico Medicine and Eli Lilly are identified as Tier 1 sponsors, with the McKinsey Health Institute serving as the sole knowledge partner. Additional sponsors include AbbVie, AniVC, AstraZeneca, BioAge Labs, Biocytogen, Cambrian Bio, Cyclarity Therapeutics, Dior, GlycanAge, Gordian Biotechnology, Human Longevity, the Institute for Healthier Living Abu Dhabi, LongeVC, Maxwell Biosciences, Nestlé, Tally Health and TruDiagnostic. Synaro Capital, The Cat Health Company and PranaGen Bioscience are supporting the meeting as Tier 4 sponsors, while Estée Lauder, Morgan Stanley, the Intrinsic Capacity Frailty & Sarcopenia Research Conference for Healthy Longevity and QuadraScope are listed as Tier 5 sponsors.

The commercial scale of that ecosystem illustrates how quickly longevity research has entered the mainstream of biomedical innovation. However, the expansion of investment also increases pressure on researchers and companies to distinguish scientifically validated approaches from premature claims. Aging is a complex, multiscale process, and interventions that appear beneficial in cells or laboratory animals may fail in humans because of differences in metabolism, immune response, disease history or treatment duration. For this reason, the most consequential discussions at meetings such as ARDD are likely to center on reproducibility, patient selection, safety, trial endpoints and the evidence required to show that a therapy changes clinically important outcomes.

Morten Scheibye-Knudsen, co-chair of ARDD and associate professor at the University of Copenhagen, said the meeting’s move to Boston marks a new stage for the conference. Boston and the surrounding region form one of the world’s most concentrated biomedical research and drug-development ecosystems, linking universities, hospitals, biotechnology companies and pharmaceutical organizations. Scheibye-Knudsen described ARDD 2026 as increasingly focused on translating discoveries into medicines, a transition that requires researchers to connect fundamental mechanisms of aging with practical therapeutic programs.

Alex Zhavoronkov, Ph.D., co-chair of ARDD and chief executive officer of Insilico Medicine, said the meeting has served for more than a decade as a platform for dialogue among academia, pharmaceutical companies, startups and investors. Insilico Medicine is officially organizing the 2026 event. The company’s role places the conference within a broader industry movement that uses artificial intelligence, large biological datasets and computational drug-discovery methods to identify targets and design candidate molecules. Such technologies may accelerate early research, but their value will ultimately depend on experimental validation and evidence from human studies.

ARDD is now in its 13th year and is described by its organizers as the world’s largest meeting dedicated to aging and longevity biotechnology. The 2026 program is intended to examine how advances in the biology of aging can be converted into research-and-development strategies and therapeutic candidates. The Nordic Aging Society, a nonprofit scientific organization dedicated to aging research and collaboration across the Nordic region and beyond, is supporting the meeting. With the field approaching a decisive phase—where molecular insights must be matched by clinical evidence—the Boston gathering will offer a high-profile test of whether longevity science can fulfill its promise of producing safer, more effective interventions for age-related disease and functional decline.

Subject of Research: Aging biology, geroscience, longevity biotechnology, drug discovery and the translation of aging research into clinical therapies.

Article Title: Pfizer Executive Ariel Feldstein to Speak at ARDD 2026 as Longevity Science Enters a New Drug-Development Era

News Publication Date: Aug. 7, 2026

Web References: https://agingpharma.org; https://mediasvc.eurekalert.org/Api/v1/Multimedia/582b0698-c395-46ef-a16b-f659f75c72f4/Rendition/low-res/Content/Public

References: ARDD 2026 announcement provided by Insilico Medicine and the ARDD organizing committee; statements attributed to Vadim Gladyshev, Morten Scheibye-Knudsen and Alex Zhavoronkov.

Image Credits: ARDD 2026

Keywords: Aging research, longevity science, geroscience, drug discovery, healthspan, biological aging, biotechnology, pharmaceutical research, clinical translation, ARDD 2026, Ariel Feldstein, Pfizer

BOSTON, Massachusetts—August 14, 2026—Alfredo Viegas, managing director of Emerging Markets Equity at Oaktree Capital, will be a featured speaker at the 13th Aging Research & Drug Discovery Meeting, known as ARDD 2026, organizers announced. The meeting will take place from October 1 to 3 at the David Rubenstein Treehouse at Harvard University, bringing together scientists, clinicians, biotechnology executives, pharmaceutical companies, entrepreneurs and institutional investors at a moment when aging research is rapidly moving from academic theory toward therapeutic development. The announcement reflects the growing financial and scientific importance of longevity biotechnology, a field focused not simply on extending lifespan but on delaying, preventing or treating the biological processes that drive multiple age-related diseases.

A central idea in modern geroscience is that aging is not a single disease, but a complex biological state that increases vulnerability to many disorders, including cancer, cardiovascular disease, neurodegeneration, diabetes and frailty. Researchers study interconnected mechanisms often described as the hallmarks of aging, including genomic instability, epigenetic alterations, mitochondrial dysfunction, cellular senescence, chronic inflammation, impaired proteostasis and the exhaustion of stem-cell reserves. If these mechanisms can be modified safely, one intervention could potentially influence several diseases simultaneously. That possibility has attracted unprecedented interest from drug developers and investors, while also raising difficult questions about clinical trial design, regulatory pathways, biomarkers and the distinction between extending life and extending healthy, functional years.

“ The biology of aging has become one of the most promising frontiers in biomedical science,” said Vadim Gladyshev, executive chair of ARDD and professor of medicine at Harvard University. He emphasized that the field must move beyond understanding aging biology to translating fundamental discoveries into interventions that improve healthspan. In practical terms, this translation requires researchers to identify molecular targets, establish causal links between those targets and disease, develop compounds that can alter the relevant pathways, and demonstrate meaningful benefits in humans. It also requires collaboration between disciplines that have traditionally operated separately, including molecular biology, clinical medicine, computational science, pharmaceutical development and health economics.

ARDD 2026 is designed to serve as a meeting point for those communities. The conference will feature academic researchers and clinical investigators alongside leaders from ten of the world’s major pharmaceutical companies, according to the organizers. Their discussions are expected to address how discoveries made in model organisms can be converted into human therapies, how biological age can be measured, and which endpoints should be used in trials of potential gerotherapeutics. Chronological age alone is a blunt measure of biological decline. Scientists are therefore developing molecular and physiological indicators, including DNA-methylation patterns, inflammatory profiles, immune function, physical performance, organ-specific measures and combinations of blood-based biomarkers. The challenge is determining which markers genuinely predict disease or functional decline and which merely correlate with aging without being useful treatment targets.

The meeting’s program also comes as the longevity sector develops increasingly sophisticated therapeutic strategies. Senolytic drugs, for example, are designed to eliminate senescent cells that have stopped dividing but remain metabolically active and release inflammatory signals known as the senescence-associated secretory phenotype. Other approaches seek to improve mitochondrial quality control, restore proteostasis, modulate nutrient-sensing pathways such as mTOR and AMPK, enhance autophagy, repair DNA damage or rejuvenate immune and stem-cell function. These strategies are scientifically distinct and may require different dosing schedules, safety assessments and clinical endpoints. A compound that improves one aspect of aging biology may not automatically produce longer survival or better health, making rigorous translational testing essential.

Morten Scheibye-Knudsen, co-chair of ARDD and associate professor at the University of Copenhagen, said the conference’s move to Boston represents a new chapter for the event. Boston and the broader Cambridge biomedical ecosystem host major universities, hospitals, biotechnology companies, pharmaceutical research centers and venture investors. That concentration creates opportunities for collaborations extending beyond conference presentations, including partnerships for target validation, drug screening, biomarker development and clinical trials. Scheibye-Knudsen said ARDD 2026 would place especially strong emphasis on translating scientific discoveries into medicines, reflecting what organizers describe as the increasing maturity of the longevity field.

Insilico Medicine is officially organizing the 2026 meeting, with Insilico Medicine and Eli Lilly serving as Tier 1 sponsors. The McKinsey Health Institute will participate as the sole knowledge partner. Additional sponsors listed by the organizers include AbbVie, AniVC, AstraZeneca, BioAge Labs, Biocytogen, Cambrian Bio, Cyclarity Therapeutics, Dior, GlycanAge, Gordian Biotechnology, Human Longevity, the Institute for Healthier Living Abu Dhabi, LongeVC, Maxwell Biosciences, Nestlé, Tally Health and TruDiagnostic. Synaro Capital, The Cat Health Company and PranaGen Bioscience are supporting the conference as Tier 4 sponsors, while Estée Lauder, Morgan Stanley, the Intrinsic Capacity Frailty & Sarcopenia Research Conference for Healthy Longevity and QuadraScope are identified as Tier 5 sponsors. The breadth of this list illustrates how aging biology now intersects with pharmaceuticals, diagnostics, consumer health, finance and technology.

Alex Zhavoronkov, co-chair of ARDD and chief executive officer of Insilico Medicine, described the meeting as a platform for dialogue among academia, pharmaceutical companies, startups and investors. Insilico has become known for applying artificial intelligence to drug discovery, including target identification, molecular design and the prioritization of compounds for experimental testing. AI systems can analyze large biological datasets, search chemical space and propose molecules with desired properties, but their predictions still require laboratory validation, animal studies and carefully controlled human trials. In longevity research, computational tools may help integrate multi-omics data—such as genomics, transcriptomics, proteomics and metabolomics—but the underlying biology remains highly interconnected. A statistically strong association is not necessarily a druggable cause, and a promising molecule must also demonstrate appropriate pharmacology, selectivity, manufacturability and safety.

The financial dimension of the meeting is particularly significant because longevity biotechnology is entering a period of heightened scrutiny. Investors are increasingly evaluating whether companies can produce conventional medical products with clear indications rather than relying solely on the broad promise of lifespan extension. Regulatory agencies generally approve treatments for defined diseases or conditions, which means developers may initially pursue indications such as frailty, fibrosis, osteoarthritis, metabolic disease or neurodegeneration. Demonstrating efficacy in these areas could provide a practical route toward therapies that also influence the broader biology of aging. Viegas’s participation, representing Oaktree Capital’s emerging-markets equity platform, adds an investment perspective to debates about capital allocation, global healthcare markets and the economic consequences of longer, healthier lives.

The Nordic Aging Society, a nonprofit scientific organization focused on aging biology and collaboration across the Nordic region and beyond, is supporting ARDD. Now in its 13th year, the meeting aims to accelerate the movement of aging research into practical research-and-development programs and therapeutic pipelines. Its Boston gathering will take place against a backdrop of growing evidence that age-related decline may be modifiable, but also of continuing uncertainty about which interventions will deliver durable benefits in humans. The scientific importance of ARDD 2026 will therefore extend beyond the announcements made on stage: it will help test whether the field can unite mechanistic biology, clinical evidence, pharmaceutical expertise and investment discipline into a coherent strategy for extending healthy human life.

Subject of Research: Aging biology, longevity biotechnology, geroscience, drug discovery and the translation of aging research into therapies.

Article Title: ARDD 2026 to Bring Aging Biology, Drug Discovery and Global Investment Together at Harvard

News Publication Date: August 14, 2026

Web References: https://agingpharma.org

Image Credits: ARDD 2026

Keywords: Aging research, longevity biotechnology, geroscience, drug discovery, healthspan, biological aging, senolytics, biomarkers, artificial intelligence, pharmaceutical research, ARDD 2026, Harvard University, Insilico Medicine, Eli Lilly, Oaktree Capital, biomedical investment, healthy longevity